Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.

Reis R, Labat L, Allard M, Boudou-Rouquette P, Chapron J, Bellesoeur A, Thomas-Schoemann A, Arrondeau J, Giraud F, Alexandre J, Vidal M, Goldwasser F, Blanchet B.

J Pharm Biomed Anal. 2018 Jun 1;158:174-183. doi: 10.1016/j.jpba.2018.05.052. [Epub ahead of print]

PMID:
29883880
2.

Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.

Cabel L, Blanchet B, Thomas-Schoemann A, Huillard O, Bellesoeur A, Cessot A, Giroux J, Boudou-Rouquette P, Coriat R, Vidal M, Saidu NEB, Golmard L, Alexandre J, Goldwasser F.

Fundam Clin Pharmacol. 2018 Feb;32(1):98-107. doi: 10.1111/fcp.12327. Epub 2017 Nov 10.

PMID:
29055166
3.

Individualized Pazopanib Dosing-Letter.

Bellesoeur A, Boudou-Rouquette P, Thomas-Schoemann A, Joly C, Tlemsani C, Vidal M, Goldwasser F, Blanchet B.

Clin Cancer Res. 2017 Oct 15;23(20):6377. doi: 10.1158/1078-0432.CCR-17-1873. No abstract available.

PMID:
29030334
4.

Letter to the editor regarding the paper by Loquai C et al. 'Use of complementary and alternative medicine: a multicenter cross-sectional study in 1089 melanoma patients'.

Fabre E, Thomas-Schoemann A, Blanchet B.

Eur J Cancer. 2017 Nov;85:158-159. doi: 10.1016/j.ejca.2017.07.035. Epub 2017 Sep 3. No abstract available.

PMID:
28877854
5.

[Therapeutic drug monitoring - 4th edition of the congress of pharmacology of anticancer drugs].

Allard M, Rousseau B, Cardoso E, Bellesoeur A, Blanchet B.

Bull Cancer. 2017 Sep;104(9):800-806. doi: 10.1016/j.bulcan.2017.06.006. Epub 2017 Jul 27. French. No abstract available.

PMID:
28756867
6.

Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.

Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S.

Invest New Drugs. 2017 Aug;35(4):537. doi: 10.1007/s10637-017-0475-7. No abstract available.

PMID:
28597150
7.

A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer.

Puszkiel A, Plé A, Huillard O, Noé G, Thibault C, Oudard S, Goldwasser F, Vidal M, Alexandre J, Blanchet B.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jul 15;1058:102-107. doi: 10.1016/j.jchromb.2017.04.014. Epub 2017 Apr 5.

PMID:
28545929
8.

Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.

Garlan F, Blanchet B, Kramkimel N, Puszkiel A, Golmard JL, Noe G, Dupin N, Laurent-Puig P, Vidal M, Taly V, Thomas-Schoemann A.

Target Oncol. 2017 Jun;12(3):365-371. doi: 10.1007/s11523-017-0491-8.

PMID:
28527094
9.

Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.

Allard M, Khoudour N, Rousseau B, Joly C, Costentin C, Blanchet B, Tournigand C, Hulin A.

J Pharm Biomed Anal. 2017 Aug 5;142:42-48. doi: 10.1016/j.jpba.2017.04.053. Epub 2017 May 1.

PMID:
28494338
10.

Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.

Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S.

Invest New Drugs. 2017 Aug;35(4):436-441. doi: 10.1007/s10637-017-0464-x. Epub 2017 Apr 10. Erratum in: Invest New Drugs. 2017 Jun 9;:.

PMID:
28396974
11.

Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.

Bonnet C, Boudou-Rouquette P, Azoulay-Rutman E, Huillard O, Golmard JL, Carton E, Noé G, Vidal M, Orvoen G, Chah Wakilian A, Villeminey C, Blanchet B, Alexandre J, Goldwasser F, Thomas-Schoemann A.

Cancer Chemother Pharmacol. 2017 May;79(5):1051-1055. doi: 10.1007/s00280-017-3291-z. Epub 2017 Mar 30.

PMID:
28361167
12.

Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients.

Puszkiel A, Noé G, Boudou-Rouquette P, Cossec CL, Arrondeau J, Giraud JS, Thomas-Schoemann A, Alexandre J, Vidal M, Goldwasser F, Blanchet B.

J Pharm Biomed Anal. 2017 May 30;139:30-36. doi: 10.1016/j.jpba.2017.02.041. Epub 2017 Feb 24.

PMID:
28260630
13.

Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer.

Henon C, Huillard O, Preta LH, Blanchet B, Goldwasser F, Alexandre J.

Clin Genitourin Cancer. 2017 Jun;15(3):e493-e495. doi: 10.1016/j.clgc.2017.01.017. Epub 2017 Feb 1. No abstract available.

PMID:
28233698
14.

Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood.

Qu Y, Noe G, Breaud AR, Vidal M, Clarke WA, Zahr N, Dervieux T, Costedoat-Chalumeau N, Blanchet B.

Future Sci OA. 2015 Nov 1;1(3):FSO26. doi: 10.4155/fso.15.24. eCollection 2015 Nov.

15.

Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.

Carton E, Noe G, Huillard O, Golmard L, Giroux J, Cessot A, Saidu NE, Peyromaure M, Zerbib M, Narjoz C, Guibourdenche J, Thomas A, Vidal M, Goldwasser F, Blanchet B, Alexandre J.

Eur J Cancer. 2017 Feb;72:54-61. doi: 10.1016/j.ejca.2016.11.027. Epub 2016 Dec 24.

PMID:
28027516
16.

Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.

Bigot F, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tlemsani C, Chapron J, Huillard O, Cessot A, Vidal M, Alexandre J, Blanchet B, Goldwasser F.

Invest New Drugs. 2017 Apr;35(2):242-246. doi: 10.1007/s10637-016-0400-5. Epub 2016 Oct 29.

PMID:
27796680
17.

[Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits].

Costedoat-Chalumeau N, Tamirou F, Le Guern V, Blanchet B, Deligny C, Piette JC.

Rev Med Interne. 2017 Feb;38(2):77-80. doi: 10.1016/j.revmed.2016.07.001. Epub 2016 Oct 13. French. No abstract available.

PMID:
27745934
18.

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.

Noé G, Bellesoeur A, Thomas-Schoemann A, Rangarajan S, Naji F, Puszkiel A, Huillard O, Saidu N, Golmard L, Alexandre J, Goldwasser F, Blanchet B, Vidal M.

Oncotarget. 2016 Oct 11;7(41):67507-67520. doi: 10.18632/oncotarget.11686.

19.

Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.

Boudou-Rouquette P, Tlemsani C, Blanchet B, Huillard O, Jouinot A, Arrondeau J, Thomas-Schoemann A, Vidal M, Alexandre J, Goldwasser F.

Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1433-1444. Epub 2016 Aug 24. Review.

PMID:
27556889
20.

Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.

Puszkiel A, White-Koning M, Dupin N, Kramkimel N, Thomas-Schoemann A, Noé G, Chapuis N, Vidal M, Goldwasser F, Chatelut E, Blanchet B.

Pharmacol Res. 2016 Nov;113(Pt A):709-718. doi: 10.1016/j.phrs.2016.06.032. Epub 2016 Jul 1.

PMID:
27378568
21.

Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker.

Da Silva F, Thomas-Schoemann A, Huillard O, Goldwasser F, Blanchet B.

Ann Oncol. 2016 Aug;27(8):1651-2. doi: 10.1093/annonc/mdw182. Epub 2016 Apr 26. No abstract available.

PMID:
27117534
22.

[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].

Bretagne M, Boudou-Rouquette P, Huillard O, Thomas-Schoemann A, Chahwakilian A, Orvoen G, Arrondeau J, Tlemsani C, Cessot A, Cabanes L, Blanchet B, Coriat R, Alexandre J, Goldwasser F.

Bull Cancer. 2016 Mar;103(3):259-72. doi: 10.1016/j.bulcan.2015.10.020. Epub 2016 Jan 29. Review. French.

PMID:
26832420
23.

Hydroxychloroquine Protects against Cardiac Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 Phosphorylation.

Bourke L, McCormick J, Taylor V, Pericleous C, Blanchet B, Costedoat-Chalumeau N, Stuckey D, Lythgoe MF, Stephanou A, Ioannou Y.

PLoS One. 2015 Dec 4;10(12):e0143771. doi: 10.1371/journal.pone.0143771. eCollection 2015.

24.

Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.

Kramkimel N, Thomas-Schoemann A, Sakji L, Golmard J, Noe G, Regnier-Rosencher E, Chapuis N, Maubec E, Vidal M, Avril M, Goldwasser F, Mortier L, Dupin N, Blanchet B.

Target Oncol. 2016 Feb;11(1):59-69. doi: 10.1007/s11523-015-0375-8.

PMID:
26208946
25.

Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.

Jallouli M, Galicier L, Zahr N, Aumaître O, Francès C, Le Guern V, Lioté F, Smail A, Limal N, Perard L, Desmurs-Clavel H, Le Thi Huong D, Asli B, Kahn JE, Pourrat J, Sailler L, Ackermann F, Papo T, Sacré K, Fain O, Stirnemann J, Cacoub P, Leroux G, Cohen-Bittan J, Sellam J, Mariette X, Blanchet B, Hulot JS, Amoura Z, Piette JC, Costedoat-Chalumeau N; Plaquenil Lupus Systemic Study Group.

Arthritis Rheumatol. 2015 May;67(8):2176-84. doi: 10.1002/art.39194.

26.

Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.

Sakji-Dupré L, Le Rhun E, Templier C, Desmedt E, Blanchet B, Mortier L.

Melanoma Res. 2015 Aug;25(4):302-5. doi: 10.1097/CMR.0000000000000162.

PMID:
25933211
27.

A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer.

Belleville T, Noé G, Huillard O, Thomas-Schoemann A, Vidal M, Goldwasser F, Alexandre J, Blanchet B.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 May 1;989:86-90. doi: 10.1016/j.jchromb.2015.03.001. Epub 2015 Mar 9.

PMID:
25813901
28.

Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.

Tlemsani C, Huillard O, Arrondeau J, Boudou-Rouquette P, Cessot A, Blanchet B, Thomas-Schoemann A, Coriat R, Durand JP, Giroux J, Alexandre J, Goldwasser F.

Expert Opin Drug Metab Toxicol. 2015 May;11(5):785-94. doi: 10.1517/17425255.2015.1030392. Epub 2015 Mar 25. Review.

PMID:
25809423
29.

Sorafenib for patients with differentiated thyroid cancer.

Huillard O, Blanchet B, Durand JP, Goldwasser F.

Lancet. 2015 Jan 17;385(9964):227. doi: 10.1016/S0140-6736(15)60053-8. No abstract available.

PMID:
25706705
30.

Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.

Arrondeau J, Huillard O, Tlemsani C, Cessot A, Boudou-Rouquette P, Blanchet B, Thomas-Schoemann A, Vidal M, Tigaud JM, Durand JP, Alexandre J, Goldwasser F.

Expert Opin Investig Drugs. 2015 May;24(5):673-87. doi: 10.1517/13543784.2015.1005736. Epub 2015 Jan 20. Review.

PMID:
25599887
31.

Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells.

Lemaitre F, Blanchet B, Latournerie M, Antignac M, Houssel-Debry P, Verdier MC, Dermu M, Camus C, Le Priol J, Roussel M, Zheng Y, Fillatre P, Curis E, Bellissant E, Boudjema K, Fernandez C.

Clin Biochem. 2015 Apr;48(6):406-11. doi: 10.1016/j.clinbiochem.2014.12.018. Epub 2015 Jan 3.

32.

Soluble VEGFR-1: a new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?).

Thomas-Schoemann A, Blanchet B, Boudou-Rouquette P, Golmard JL, Noé G, Chenevier-Gobeaux C, Lebbe C, Pages C, Durand JP, Alexandre J, Goldwasser F, Guibourdenche J, Vidal M.

J Clin Pharmacol. 2015 Apr;55(4):478-9. doi: 10.1002/jcph.429. Epub 2014 Dec 30. No abstract available.

PMID:
25401221
33.

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.

Narjoz C, Cessot A, Thomas-Schoemann A, Golmard JL, Huillard O, Boudou-Rouquette P, Behouche A, Taieb F, Durand JP, Dauphin A, Coriat R, Vidal M, Tod M, Alexandre J, Loriot MA, Goldwasser F, Blanchet B.

Invest New Drugs. 2015 Feb;33(1):257-68. doi: 10.1007/s10637-014-0178-2. Epub 2014 Oct 25.

PMID:
25344452
34.

Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better.

Cessot A, Blanchet B, Goldwasser F.

Ann Oncol. 2014 Oct;25(10):2093-4. doi: 10.1093/annonc/mdu261. Epub 2014 Jul 23. No abstract available.

PMID:
25057169
35.

Sorafenib in thyroid cancer patients: learning from toxicity.

Huillard O, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A, Wassermann J, Goldwasser F.

Oncologist. 2014 Aug;19(8):e3. doi: 10.1634/theoncologist.2014-0156. Epub 2014 Jul 22. No abstract available.

36.

Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.

Huillard O, Boissier E, Blanchet B, Thomas-Schoemann A, Cessot A, Boudou-Rouquette P, Durand JP, Coriat R, Giroux J, Alexandre J, Vidal M, Goldwasser F.

Expert Opin Drug Saf. 2014 May;13(5):663-73. doi: 10.1517/14740338.2014.907270. Epub 2014 Apr 3. Review.

PMID:
24693873
37.

Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach.

Gérard C, Stocco J, Hulin A, Blanchet B, Verstuyft C, Durand F, Conti F, Duvoux C, Tod M.

AAPS J. 2014 May;16(3):379-91. doi: 10.1208/s12248-014-9577-8. Epub 2014 Feb 14.

38.

Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.

Bellesoeur A, Carton E, Mir O, Groussin L, Blanchet B, Billemont B, Clerc J, Goldwasser F.

Invest New Drugs. 2014 Jun;32(3):569-72. doi: 10.1007/s10637-013-0052-7. Epub 2014 Jan 8.

PMID:
24399106
39.

Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).

Hénin E, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A, Freyer G, Vidal M, Goldwasser F, Tod M.

Cancer Chemother Pharmacol. 2014 Feb;73(2):287-97. doi: 10.1007/s00280-013-2352-1. Epub 2013 Nov 20.

PMID:
24253177
40.

Drug interactions with solid tumour-targeted therapies.

Thomas-Schoemann A, Blanchet B, Bardin C, Noé G, Boudou-Rouquette P, Vidal M, Goldwasser F.

Crit Rev Oncol Hematol. 2014 Jan;89(1):179-96. doi: 10.1016/j.critrevonc.2013.08.007. Epub 2013 Aug 28. Review.

PMID:
24041628
41.

An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.

Zhen Y, Thomas-Schoemann A, Sakji L, Boudou-Rouquette P, Dupin N, Mortier L, Vidal M, Goldwasser F, Blanchet B.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jun 1;928:93-7. doi: 10.1016/j.jchromb.2013.03.017. Epub 2013 Mar 25.

PMID:
23602929
42.

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.

Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, Durand JP, Coriat R, Dauphin A, Vidal M, Tod M, Loriot MA, Goldwasser F, Blanchet B.

PLoS One. 2012;7(8):e42875. doi: 10.1371/journal.pone.0042875. Epub 2012 Aug 13.

43.

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

Pécuchet N, Lebbe C, Mir O, Billemont B, Blanchet B, Franck N, Viguier M, Coriat R, Tod M, Avril MF, Goldwasser F.

Br J Cancer. 2012 Jul 24;107(3):455-61. doi: 10.1038/bjc.2012.287. Epub 2012 Jul 5.

44.

Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.

Boudou-Rouquette P, Ropert S, Mir O, Coriat R, Billemont B, Tod M, Cabanes L, Franck N, Blanchet B, Goldwasser F.

Oncologist. 2012;17(9):1204-12. Epub 2012 Jul 2.

45.

Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.

Mir O, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J, Ropert S, Vidal M, Pol S, Chaussade S, Goldwasser F.

PLoS One. 2012;7(5):e37563. doi: 10.1371/journal.pone.0037563. Epub 2012 May 30.

46.

Pharmacokinetics of caspofungin in two patients with burn injuries.

Jullien V, Blanchet B, Benyamina M, Tod M, Vinsonneau C.

Antimicrob Agents Chemother. 2012 Aug;56(8):4550-1. doi: 10.1128/AAC.00039-12. Epub 2012 May 14. No abstract available.

47.

Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma.

Mir O, Boudou-Rouquette P, Larousserie F, Blanchet B, Babinet A, Anract P, Goldwasser F.

Anticancer Drugs. 2012 Aug;23(7):745-8. doi: 10.1097/CAD.0b013e3283514b8c.

PMID:
22331039
48.

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.

Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, Rodrigues MJ, Rousseau B, Blanchet B, Goldwasser F.

Invest New Drugs. 2012 Oct;30(5):2046-9. doi: 10.1007/s10637-011-9764-8. Epub 2011 Oct 29.

PMID:
22038662
49.

Saturable absorption of sorafenib in patients with solid tumors: a population model.

Hornecker M, Blanchet B, Billemont B, Sassi H, Ropert S, Taieb F, Mir O, Abbas H, Harcouet L, Coriat R, Dauphin A, Goldwasser F, Tod M.

Invest New Drugs. 2012 Oct;30(5):1991-2000. doi: 10.1007/s10637-011-9760-z. Epub 2011 Oct 18.

PMID:
22006162
50.

How to improve the hygienic quality of forages for horse feeding.

Séguin V, Garon D, Lemauviel-Lavenant S, Lanier C, Bouchart V, Gallard Y, Blanchet B, Diquélou S, Personeni E, Ourry A.

J Sci Food Agric. 2012 Mar 15;92(4):975-86. doi: 10.1002/jsfa.4680. Epub 2011 Oct 17.

PMID:
22002664

Supplemental Content

Loading ...
Support Center